Analysts Say Lupin, Cipla May Benefit From Perrigo’s Asthma Drug Recall
Capsules are laid out for inspection on a production line (Photographer: Tomohiro Ohsumi/Bloomberg)

Analysts Say Lupin, Cipla May Benefit From Perrigo’s Asthma Drug Recall

Analysts expect Perrigo Co.’s voluntary recall of a key asthma drug to provide an opportunity for Lupin Ltd. and Cipla Ltd.—the two Indian pharmaceutical companies that received the U.S. health reg...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.